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Endovascular Treatment With or Without Prior Intravenous Alteplase
for Acute Ischemic Stroke
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Esmee Venema, MD; Kilian M. Treurniet, MD; Omid Eshghi, MD; H. Bart van der Worp, MD, PhD; Aad van der Lugt, MD, PhD;
Yvo B. W. E. M. Roos, MD, PhD; Charles B. L. M. Majoie, MD, PhD; Diederik W. J. Dippel, MD, PhD; Bob Roozenbeek, MD, PhD;**
Jonathan M. Coutinho, MD, PhD**; on behalf of the MR CLEAN Registry Investigators***
Background-—It is unclear whether intravenous thrombolysis (IVT) with alteplase before endovascular treatment (EVT) is beneﬁcial
for patients with acute ischemic stroke caused by a large vessel occlusion. We compared clinical and procedural outcomes, safety,
and workﬂow between patients treated with both IVT and EVT and those treated with EVT alone in routine clinical practice.
Methods and Results-—Using multivariable regression, we evaluated the association of IVT+EVT with 90-day functional outcome
(modiﬁed Rankin Scale), mortality, reperfusion, ﬁrst-pass effect, and symptomatic intracranial hemorrhage in the MR CLEAN
(Multicenter Randomised Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands) Registry. Of
1485 patients, 1161 (78%) were treated with IVT+EVT, and 324 (22%) with EVT alone. Patients treated with IVT+EVT had atrial
ﬁbrillation less often (16% versus 44%) and had better pre-stroke modiﬁed Rankin Scale scores (pre-stroke modiﬁed Rankin Scale
0: 73% versus 52%) than those treated with EVT alone. Procedure time was shorter in the IVT+EVT group (median 62 versus
68 minutes). Nontransferred IVT+EVT patients had longer door-to-groin-puncture times (median 105 versus 94 minutes). IVT+EVT
was associated with better functional outcome (adjusted common odds ratio 1.47; 95% CI: 1.10–1.96) and lower mortality
(adjusted odds ratio 0.58; 95% CI: 0.40–0.82). Successful reperfusion, ﬁrst-pass effect, and symptomatic intracranial hemorrhage
did not differ between groups.
Conclusions-—In this observational study, patients treated with IVT+EVT had better clinical outcomes than patients who received
EVT alone. This ﬁnding may demonstrate a true beneﬁt of IVT before EVT, but its interpretation is hampered by the possibility of
residual confounding and selection bias. Randomized trials are required to properly assess the effect of IVT before EVT. ( J Am
Heart Assoc. 2019;8:e011592. DOI: 10.1161/JAHA.118.011592.)
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E ndovascular treatment (EVT) has become standard of carefor patients with acute ischemic stroke caused by an
intracranial large vessel occlusion of the anterior circulation.1
Patients included in the EVT trials received intravenous throm-
bolysis (IVT) with alteplase as standard care, unless they had a
contraindication for IVT. Hence, all major guidelines recommend
IVT in eligible patients before EVT.2 In a recent meta-analysis of
randomized trials, the effect of EVT was not inﬂuenced by IVT,
raising the question of whether IVT is beneﬁcial to patients with a
large vessel occlusion.1 Theoretical advantages of IVT before EVT
include early reperfusion, faster procedural times, lysis of distal
emboli, and improved microvascular reperfusion.3 Potential
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disadvantages include delayed initiation of EVT, thrombus
fragmentation, major bleeding, potential neurotoxicity, and
disruption of the blood–brain barrier.4–6
Several studies examined the efﬁcacy and safety of IVT
before EVT, but the sample sizes of most studies were
relatively small, and their results were inconclusive.7–10
The aim of our study was to compare clinical and procedural
outcomes, safety, and workﬂow between acute ischemic stroke
patients with a large vessel occlusion treated with both IVT and
EVT to those treated with EVT alone using data of the MR CLEAN
(Multicenter Randomised Controlled Trial of Endovascular Treat-
ment for Acute Ischemic Stroke in the Netherlands) Registry.
Methods
Data, Materials, and Code Disclosure Statement
Data will not be made available to other researchers for
purposes of reproducing the results or replicating the
procedure, because no patient approval has been obtained
for sharing coded data. However, syntax and output ﬁles of
statistical analyses may be made available upon request.
Study Design
Details of the MR CLEAN Registry have been reported
previously.11 Brieﬂy, the MR CLEAN Registry is an ongoing,
nationwide, multicenter, prospective, observational phase IV
study for centers that provide EVT in The Netherlands. Data
are collected from consecutive patients who underwent EVT in
18 hospitals. All imaging of patients in the MR CLEAN Registry
is adjudicated by an imaging core laboratory, whose members
are blinded to clinical ﬁndings, except for symptom side.
Safety parameters are scored by the complication committee,
whose members are blinded to treatment center. A central
medical ethics committee evaluated the study protocol of the
MR CLEAN Registry and granted permission to carry out the
study as a registry.
Study Population and Treatment
We included adult patients who were treated in a MR CLEAN
trial center between March 2014 and June 2016, with a large
vessel occlusion of the anterior circulation conﬁrmed on
computed tomography angiography or magnetic resonance
angiography (intracranial carotid artery [ICA/ICA-T], middle
cerebral artery [M1/M2], anterior cerebral artery [A1/A2]),
and who underwent groin puncture within 6.5 hours after
symptom onset. We excluded patients for whom it was
unknown whether they received IVT.
IVT (0.9 mg/kg alteplase over 1 hour with 10% initial bolus)
was administered at the ﬁrst hospital of arrival, according to
national guidelines. EVT consisted of mechanical thrombec-
tomy with a stent retriever and/or thrombus aspiration, with or
without local delivery of a thrombolytic agent.
Outcome Measures
The primary outcome was the modiﬁed Rankin Scale (mRS)
score at 90 days. Secondary outcomes were an mRS score of
0 to 2 (functional independence) at 90 days; change in score
on the National Institutes of Health Stroke Scale (NIHSS) from
baseline to 24 to 48 hours (delta NIHSS); door-(intervention
center)-to-groin-puncture time; procedure time; onset-to-last-
contrast-bolus time; ﬁrst-pass effect (single pass/use of the
device as ﬁrst line of EVT, complete reperfusion of the large
vessel occlusion and its downstream territory [eTICI 3] and no
use of rescue therapy after use of the device)12; reperfusion
before start of EVT (deﬁned as a score ≥2B on the extended
Thrombolysis in Cerebral Ischemia scale [eTICI] on ﬁrst digital
subtraction angiography); and successful reperfusion post-
EVT (deﬁned as an eTICI score ≥2B or ≥2C).13
Procedure time was deﬁned as the moment of puncture of
the femoral artery to successful reperfusion (eTICI ≥2B) or last
contrast bolus (when successful reperfusion was not achieved
or no target occlusion was seen during the intervention).
Clinical Perspective
What Is New?
• The question of whether intravenous thrombolysis (IVT)
should still be administered before endovascular treatment
(EVT) in ischemic stroke patients was investigated in a large,
nationwide registry of patients who underwent EVT, reﬂect-
ing daily clinical practice.
• IVT administration appeared to delay the time until groin
puncture in nontransferred patients.
• Various aspects of this debate, including clinical and safety
outcomes, workﬂow implications, ﬁrst-pass effect (success-
ful reperfusion on ﬁrst pass without rescue medication), and
reperfusion of the occluded vessel before EVT were explored
in 1 comprehensive study.
What Are the Clinical Implications?
• In addition to having better clinical outcomes, patients
treated with IVT+EVT more often had reperfusion of the
occluded vessel before EVT than patients treated with EVT
alone.
• IVT remains the only available reperfusion therapy in about
6% of all patients, in whom the clot was not accessible
because of technical reasons; however, successful reperfu-
sion and ﬁrst-pass effect did not differ between groups,
implying that IVT does not facilitate the thrombectomy
procedure.
• Until results of ongoing randomized trials are published,
current guidelines should remain unchanged.
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Onset-to-last-contrast-bolus time was deﬁned as the duration
from symptom onset or time of last seen well to successful
reperfusion or last contrast bolus. Safety outcomes were
mortality at 90 days, severe extracranial hemorrhage (ie,
requiring surgery or blood transfusion), and symptomatic
intracranial hemorrhage (sICH) according to the Heidelberg
Bleeding Classiﬁcation.14
Statistical Analysis
We compared patients treated with IVT+EVT with patients
treated with EVT alone. For intergroup comparison, we used a
v2 test, Fisher’s exact test, Student t test, or Mann–Whitney U
test. The mRS scores of patients treated with IVT+EVT were
compared with those of patients treated with EVT alone by
means of ordinal logistic regression. Binary outcomes were
analyzed with logistic regression analysis and continuous
outcomes with linear regression analysis. We made adjust-
ments based on theoretical identiﬁcation, known association
with outcome, and empirical identiﬁcation (ie, baseline imbal-
ances). For all analyses, wemade adjustments in amultivariable
model for age, baseline NIHSS, history of diabetes mellitus,
pre-stroke mRS, prior use of anticoagulant medication, onset-
to-ﬁrst-noncontrast-computed-tomography time, center (in
case of sufﬁcient [≥1] outcome events), and additional baseline
imbalances (P<0.05) in the patients’ medical histories. For
clinical outcomemeasures, wemade additional adjustments for
baseline mean arterial pressure, occlusion location, collateral
score,15 and transfer from a primary stroke center. For door-to-
groin-puncture time, procedure time, onset-to-last-contrast-
bolus time, ﬁrst-pass effect, reperfusion before start of EVT, and
successful reperfusion, we additionally adjusted for occlusion
location and transfer from a primary stroke center. For sICH and
severe extracranial hemorrhage, we additionally adjusted for
baselinemean arterial pressure, prior use of antiplatelet agents,
and Alberta Stroke Program Early CT Score. We tested for
collinearity between all variables in all analyses by measuring
the variance inﬂation factor.
In a supplementary analysis, we compared the distribution
of occlusion locations in patients with reperfusion before start
of EVT to those without.
Missing data were imputed using multiple imputation
based on relevant covariates and outcome. Adjusted (com-
mon) odds ratios [a(c)ORs] are reported with 95% CIs and all
P values are 2-sided. Statistical analyses were performed with
Stata software, version 14.1 (StatCorp, TX), and IBM SPSS
Statistics for Windows, Version 24.0.
Sensitivity Analyses
We performed 2 sensitivity analyses. First, we conducted
a 1:1 propensity score matching analysis to evaluate the
association between IVT and functional outcome. Propensity
scores representing the probability of receiving IVT were
calculated for each patient in each multiple imputed data set,
using a logistic regression model, based on the covariates
used for the adjustments in our primary analysis. Patients
from the EVT alone group were matched to patients in the
IVT+EVT group in a 1:1 nearest-neighbor matching of the logit
of the propensity score, with a caliper width of 0.20. Matching
was performed without replacement and unpaired patients
were excluded. We used an ordinal logistic regression analysis
to compare functional outcomes of patients treated with
IVT+EVT and EVT alone.
To explore residual confounding, we performed a second
sensitivity analysis, in which we stratiﬁed for “history of atrial
ﬁbrillation.” In this analysis, we used the outcome variables
mRS at 90 days, functional independence at 90 days, mor-
tality at 90 days, sICH, and eTICI ≥2B.
Results
During the study period, 1628 patients were recorded in the
MR CLEAN Registry, of whom 140 did not meet the inclusion
criteria. We further excluded 3 patients because it was
unknown whether they had been treated with IVT. Of the
1485 included patients, 1161 (78%) were treated with
IVT+EVT and 324 (22%) with EVT alone (Figure 1).
The most common reasons for withholding IVT were
coagulation abnormalities and/or antithrombotic treatment
(50%), recent surgery (15%), and presentation exceeding
4.5 hours after symptom onset or last seen well (14%)
(Table 1).
Patients in the IVT+EVT group were younger (median 70
years versus 72 years, P=0.03), had less severe deﬁcits
(median NIHSS 16 versus 17, P<0.01), less often had atrial
ﬁbrillation (16% versus 44%, P<0.01) and previous ischemic
stroke (14% versus 26%, P<0.01) than patients treated with
EVT alone (Table 2). Patients treated with IVT+EVT also had a
better pre-stroke mRS (mRS 0: 73% versus 52%, P<0.01).
In total, 656 (57%) patients with IVT+EVT were transferred
from a primary stroke center, compared with 151 (47%)
patients treated with EVT alone (P<0.01) (Table 3). The
median door-to-needle time in patients treated with IVT+EVT
was 25 minutes. Onset-to-noncontrast-computed-tomogra-
phy time (median 67 versus 83 minutes, P<0.01) and onset-
to-groin-puncture time (median 206 versus 215 minutes,
P=0.04) were shorter in the IVT+EVT group.
The scores on the mRS at 90 days were more favorable in
patients in the IVT+EVT group than in the EVT-alone group, and
this difference persisted after adjustment for potential con-
founders (acOR 1.47; 95% CI: 1.10–1.96, Table 4, Figure 2).
Functional independence at 90 days was achieved in 41% of
patients with IVT+EVT, compared with 29% of patients with EVT
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alone (aOR 1.32; 95% CI: 0.85–1.87). Delta NIHSS was larger
(adjusted b 1.5; 95% CI: 2.6 to 0.3) and mortality was
lower in the IVT+EVT group (aOR 0.58; 95% CI: 0.40–0.82).
Among nontransferred patients, median door-to-groin-
puncture time was longer in the IVT+EVT group (105 versus
94 minutes; adjusted b 9.5; 95% CI: 0.5–18.5), while among
transferred patients this was 47 minutes in both groups. We
found no association between prior IVT and door-to-groin-
puncture time for transferred patients only (adjusted b 0.5;
95% CI: 7.3 to 8.2), nor between prior IVT and onset-to-last-
contrast-bolus time (adjusted b 3.5; 95% CI: 12.8 to 5.9).
There also was no difference in the proportion of patients with
ﬁrst-pass effect (17% versus 16%; aOR 1.22; 95% CI: 0.79–
1.90). We did ﬁnd a faster median procedure time (62 versus
68 minutes, adjusted b 6.2; 95% CI: 11.0 to 1.3) in the
IVT+EVT group. Reperfusion before start of EVT occurred
more often in the IVT+EVT group than in the EVT-alone group
(8.4% versus 2.8%, aOR 3.14; 95% CI: 1.47–6.73) (Table 4).
In the supplementary analysis in 85 of the 97 IVT+EVT
patients who had reperfusion before EVT and in whom the
occlusion location was known, 61 (72%) had a distal M1, M2,
or M3 occlusion (Table 5).
The risk of severe extracranial hemorrhage (2.4% versus 1.5%,
aOR 1.96; 95% CI: 0.66–5.81) and sICH (5.9% versus 5.3%, aOR
1.20;95%CI: 0.64–2.25) did not differ betweengroups (Table 4).
Sensitivity Analyses
After applying 1:1 matching in each multiple imputed data set,
sample sizes of both the IVT+EVT and EVT alone group ranged
between 299 and 305. Baseline characteristics were similar in
the 2 matched groups, with signiﬁcant differences remaining
in atrial ﬁbrillation, prior use of direct oral anticoagulants, and
prior use of vitamin K antagonists (Table 6). Prior IVT was still
associated with better functional outcome at 90 days (cOR
1.42; 95% CI: 1.03–1.96).
Figure 1. Flowchart of patient selection. EVT indicates endovascular treatment; IVT, intravenous
thrombolysis; MR CLEAN, a Multicenter Randomized Controlled trial of Endovascular Treatment for Acute
Ischemic Stroke in The Netherlands.
Table 1. Reported Reasons for Withholding IVT
Reason for Withholding IVT* Total (n=324), n (%)
Coagulation abnormalities and/
or antithrombotic treatment
163 (50)
Recent surgery 48 (15)
Time from symptom onset or
last seen well exceeds 4.5 h
46 (14)
Recent ischemic stroke 29 (9.0)
Recent traumatic injury
or current hemorrhage
20 (6.2)
Recent gastrointestinal
or urogenital hemorrhage
12 (3.7)
Other, such as allergy for IVT,
cerebellar metastasis,
endocarditis, pregnancy
10 (3.1)
Recent ICH 8 (2.5)
SBP ≥185 mm Hg and/
or DBP ≥110 mm Hg
7 (2.2)
Unknown 5 (1.5)
DBP indicates diastolic blood pressure; ICH, intracranial hemorrhage; IVT, intravenous
thrombolysis; SBP, systolic blood pressure.
*More than 1 reason may have been reported per patient.
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We next stratiﬁed the analysis for atrial ﬁbrillation. Among
327 patients with atrial ﬁbrillation, 186 underwent IVT+EVT
and 141 EVT alone. Of the 1137 patients without atrial
ﬁbrillation, 958 underwent IVT+EVT and 179 EVT alone. A
comparison of baseline characteristics within the strata is
shown in Table 7. The association between prior IVT and
better functional outcome at 90 days remained statistically
signiﬁcant among patients without atrial ﬁbrillation (acOR
Table 2. Baseline Characteristics
IVT+EVT (n=1161) EVT (n=324) P Value
Age (y), median (IQR) 70 (59–79) 72 (63–80) 0.03
Men, n (%) 621 (54) 171 (53) 0.82
NIHSS, median (IQR)* 16 (11–20) 17 (13–20) <0.01
Systolic BP, mean mm Hg (SD)† 150 (24) 149 (26) 0.85
Diastolic BP, mean mm Hg (SD)‡ 82 (15) 82 (17) 0.77
Medical history
Atrial fibrillation, n (%) 186/1144 (16) 141/320 (44) <0.01
Diabetes mellitus, n (%) 197/1155 (17) 56/321 (17) 0.87
Hypertension, n (%) 562/1145 (49) 180/321 (56) 0.03
Ischemic stroke, n (%) 164/1154 (14) 83/322 (26) <0.01
Myocardial infarction, n (%) 163/1142 (14) 64/314 (20) <0.01
Peripheral artery disease, n (%) 99/1139 (8.7) 36/318 (11) 0.15
Pre-stroke mRS, n (%) <0.01
0 826/1138 (73) 165/320 (52)
1 132/1138 (12) 57/320 (18)
2 70/1138 (6.2) 38/320 (12)
≥3 110/1138 (9.7) 60/320 (19)
Medication
Direct oral anticoagulants, n (%) 10/1141 (0.9) 27/318 (8.5) <0.01
Vitamin K antagonists, n (%) 70/1150 (6.1) 120/324 (37) <0.01
Antiplatelets, n (%) 391/1146 (34) 100/320 (31) 0.34
Imaging
Occlusion location on CTA, n (%) 0.32
ICA 70/1101 (6.4) 12/307 (3.9)
ICA-T 241/1101 (22) 71/307 (23)
M1 637/1101 (58) 186/307 (61)
M2 142/1101 (13) 33/307 (11)
Otherk 11/1101 (1.0) 5/307 (1.6)
ASPECTS, median (IQR)§ 9 (7–10) 9 (7–10) 0.76
Collateral score, n (%) 0.74
Grade 0 72/1105 (6.7) 24/303 (7.9)
Grade 1 365/1105 (34) 95/303 (31)
Grade 2 41/1105 (39) 117/303 (39)
Grade 3 221/1105 (21) 67/303 (22)
ASPECTS indicates Alberta Stroke Program Early CT Score; BP, blood pressure; CTA, computed tomography angiography; EVT, endovascular treatment; ICA, internal carotid artery; ICA-T,
terminal internal carotid artery; IQR, interquartile range; IVT, intravenous thrombolysis; M1, middle cerebral artery segment 1; M2, middle cerebral artery segment 2; mRS, modiﬁed Rankin
Scale; NIHSS, National Institutes of Health Stroke Scale.
Missing: *30; †42; ‡47; §64.
kOther: occlusions in segment 1 or 2 of the anterior cerebral artery (A1: n=3; A2: n=3) or segment 3 of the middle cerebral artery (M3, n=9), or no occlusion visible (n=12) on CTA after
adjudication by the imaging core laboratory.
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1.72; 95% CI: 1.23–2.42, Table 8). However, among patients
with atrial ﬁbrillation, there was no association between prior
IVT and functional outcome (acOR 1.06; 95% CI: 0.63–1.81).
We also found a higher percentage of sICH in patients with
atrial ﬁbrillation who were treated with IVT+EVT, but this
difference was not statistically signiﬁcant (5.9% versus 2.8%,
aOR 2.18; 95% CI: 0.60–7.91).
Discussion
In our study—in which we compared clinical and procedural
outcomes, safety, and workﬂow in patients with acute
ischemic stroke and an intracranial large vessel occlusion of
the anterior circulation treated with IVT+EVT to those treated
with EVT alone—we found that the combination of EVT with
IVT was associated with a better clinical outcome than
treatment with EVT alone.
A number of observational studies have previously
addressed the additional beneﬁt of IVT before EVT. These
studies mostly had small sample sizes (range: 66–500
patients, with the exception of 1 study of 1166 patients)
and had varying results.7–9,16–18 A post hoc, pooled analysis
of the SWIFT (Solitaire With the Intention for Thrombectomy)
and STAR (Solitaire Flow Restoration Thrombectomy for Acute
Revascularization) studies showed no statistically signiﬁcant
beneﬁt of IVT followed by EVT over EVT alone.9 However,
contrary to our study, the effect of IVT was awaited before
initiating EVT in the majority of cases, possibly decreasing the
chances of good functional outcome. Two other studies
performed a propensity score matching analysis comparing
patients who received IVT before EVT with IVT-eligible patients
who underwent EVT alone, and also found no difference in
functional independence between the 2 groups.8,10 In only 2
studies with data of 66 and 131 patients, a score on the mRS
of 0 to 2 at 90 days was more common in the IVT+EVT group,
which is in line with our results.16,17 Notably, all previous
studies used a dichotomized mRS as outcome measure for
regression analyses, which has less statistical power than an
ordinal analysis, and may thus lead to false-negative results.
In accordance with previous studies, prior use of IVT was
not associated with a higher percentage of successful
reperfusion,8,9,18 nor was it associated with a higher percent-
age of ﬁrst-pass effect, a relatively new measure of successful
thrombectomy.12 Conversely, procedure times were shorter in
the IVT+EVT group. This implies that it may have been more
difﬁcult to gain intracranial access in the EVT alone group. It
further implies that IVT does not facilitate the procedure by
softening the thrombus. The latter could also have been
inﬂuenced by differences in stroke cause between the 2
groups (ie, caused by a higher percentage of atrial ﬁbrillation
in the EVT-alone group) potentially leading to different clot
characteristics.19 However, if that were the case, the
differences in successful reperfusion and ﬁrst-pass effect
would have been larger. Also, this association between clot
characteristics and cause remains unclear,19 and we did
account for this imbalance in our multivariable analysis.
Further, it is possible that the higher percentage of oral
anticoagulation use in the EVT-only group inﬂuenced the
occurrence of successful reperfusion, despite our attempts to
adjust for this imbalance. However, there is currently no
evidence that oral anticoagulation use and successful reper-
fusion are associated with one another.
We found that patients in the IVT+EVT group more
frequently had reperfusion before start of EVT (eTICI ≥2B on
Table 3. Workﬂow* and Treatment Characteristics
IVT+EVT (n=1161) EVT (n=324) P Value
Transferred from primary stroke center, n (%) 656 (57) 151 (47) <0.01
Onset-to-first-NCCT time† 67 (51–103) 83 (52–142) <0.01
Door-to-needle time‡ 25 (19–33) NA
Onset-to-groin-puncture timek 206 (160–260) 215 (158–294) 0.04
Door-to-groin-puncture timek§ 128 (97–165) 115 (85–165) 0.08
Performed procedure, n (%)
Catheterization—no access to target occlusion 64 (5.5) 16 (5.0) <0.01
DSA—no target occlusion present 108 (9.3) 11 (3.4)
Thrombectomy—thrombus retrieval attempted 983 (85) 294 (91)
Other—procedure ended before attempt 6 (0.5) 3 (0.9)
DSA indicates digital subtraction angiography; EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous thrombolysis; NA, not applicable; NCCT, noncontrast computed
tomography.
*All times are in minutes—median (IQR).
Missing: †495; ‡319; §447.
kIncludes both transferred and nontransferred patients; door-time is door of ﬁrst hospital.
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ﬁrst digital subtraction angiography) than in the EVT-alone
group. Reperfusion before start of EVT in the ESCAPE
(Endovascular Treatment for Small Core and Anterior Circula-
tion Proximal Occlusion with Emphasis on Minimizing CT to
Recanalization Times) trial and MR CLEAN trial was found in
4.8% and 3.7% of patients, respectively, compared with 8% in
our study.20,21 Our supplementary analysis showed that
patients with reperfusion before EVT had more distally located
occlusions, supporting the hypothesis that IVT is most
effective in more distally located thrombi.22 However, these
numbers are small and there may be underreporting of those
patients who recovered before EVT because these patients
were not included in the MR CLEAN Registry. Moreover,
results of the recent EXTEND-IA TNK (Tenecteplase versus
Alteplase before Endovascular Therapy for Ischemic Stroke)
study suggest that tenecteplase may be a more effective
ﬁbrinolytic drug than alteplase in patients with a large vessel
occlusion.23 Whether tenecteplase can replace alteplase as
the preferred drug for IVT requires further study.24 Con-
versely, the use of IVT before EVT may also pose a higher risk
of emboli migrating to a previously uninvolved territory or
thrombus migration to more distal arterial branches that
cannot be reached with EVT, which is associated with a worse
prognosis.25 In our study, embolization to a new territory and
thrombus migration were not documented. However, the
postprocedural eTICI score of ≥2C was similar in both groups.
This ﬁnding suggests that IVT contributes mainly to faster
recanalization, rather than causing thrombus migration.
The median door-to-groin-puncture time was 11 minutes
longer in nontransferred patients in the IVT+EVT group, which
indicates that administration of IVT might contribute to a small
delay in start of EVT. This difference was shorter than the 32-
minute mean delay in the STAR (Solitaire FR Thrombectomy for
Acute Revascularization) trial.26 This suggests that, with the
increased experience in intervention centers, delayed start of
EVT because of IVT administration has become less of an issue.
Table 4. Primary, Secondary,* and Safety Outcomes Among Patients Treated With IVT+EVT Versus EVT Alone
IVT+EVT (n=1161) EVT (n=324) P Value (c)OR/b (95% CI) Adjusted (c)OR/b (95% CI)†
Primary outcome
mRS at 90 d, median (IQR)‡ 3 (2–6) 4 (2–6) <0.01 1.80 (1.43–2.26) 1.47 (1.10–1.96)††
Secondary outcomes
mRS 0–2 at 90 d, n (%) 431/1061 (41) 86/299 (29) <0.01 1.65 (1.25–2.17) 1.32 (0.85–1.87)††
ΔNIHSS, median (IQR)§ 4 (9 to 0) 3 (8 to 1) 0.02 0.9 (1.9 to 0.2) 1.5 (2.6 to 0.3)††
Door-intervention center-to-groin-puncture
time for transferred patientsk
47 (31–69) 47 (30–71) 0.72 0.8 (7.2 to 5.7) 0.5 (7.3 to 8.2)‡‡
Door-intervention center-to-groin-puncture
time for nontransferred patients¶
105 (79–130) 94 (73–125) 0.08 10.5 (2.2–18.8) 9.5 (0.5–18.5)‡‡
Procedure time# 62 (39–87) 68 (45–95) <0.01 5.6 (9.9 to 1.3) 6.2 (11.0 to 1.3)‡‡
Onset-to-last-contrast-bolus time** 265 (215–324) 277 (221–355) <0.01 19.6 (29.5 to 9.7) 3.5 (12.8 to 5.9)‡‡
First-pass effect¶¶ 147/842 (17) 41/259 (16) 0.543 1.20 (0.83–1.74) 1.22 (0.79–1.90)§§
Reperfusion (eTICI ≥2B) before start of EVT, n (%) 97/1161 (8.4) 9/324 (2.8) <0.01 3.19 (1.59–6.39) 3.14 (1.47–6.73)§§
Successful reperfusion post-EVT (eTICI ≥2B), n (%) 672/1143 (59) 175/321 (54) 0.17 1.19 (0.92–1.52) 1.05 (0.77–1.43)‡‡
Post-EVT eTICI ≥2C, n (%) 456/1143 (40) 120/321 (37) 0.42 1.11 (0.86–1.43) 0.98 (0.72–1.33)‡‡
Safety outcomes
Mortality at 90 d, n (%) 275/1161 (24) 122/324 (38) <0.01 0.51 (0.40–0.67) 0.58 (0.40–0.82)††
Severe extracranial hemorrhage, n (%) 28/1161 (2.4) 5/324 (1.5) 0.35 1.58 (0.60–4.12) 1.96 (0.66–5.81)kk
Symptomatic ICH, n (%) 69/1161 (5.9) 17/324 (5.3) 0.64 1.14 (0.66–1.97) 1.20 (0.64–2.25)kk
(c)OR indicates common odds ratio; eTICI, extended Thrombolysis in Cerebral Ischemia scale; EVT, endovascular treatment; ICH, intracranial hemorrhage; IQR, interquartile range; IVT,
intravenous thrombolysis; mRS, modiﬁed Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale; ΔNIHSS, NIHSS at 24 to 48 hours minus baseline NIHSS.
*All times are in minutes—median (IQR).
†All analyses were adjusted for: age (y), baseline NIHSS, history of atrial ﬁbrillation, diabetes mellitus, hypertension, ischemic stroke, myocardial infarction, pre-stroke mRS, prior use of
anticoagulant medication, onset-to-ﬁrst noncontrast CT (NCCT) time.
Missing: ‡125; §167; k35; ¶96; #156; **87.
††Additionally adjusted for: baseline mean arterial pressure (MAP), occlusion location, collateral score, transfer from a primary stroke center, center.
‡‡Additionally adjusted for: occlusion location, transfer from a primary stroke center, center.
§§Additionally adjusted for: occlusion location, transfer from a primary stroke center.
kkAdditionally adjusted for: baseline MAP, prior use of antiplatelet agents, Alberta Stroke Program Early CT Score.
¶¶In patients with at least 1 attempt at thrombectomy with a device (n=1101/1267).
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Our study showed a reduction in mortality in favor of
IVT+EVT versus EVT alone, which is in contrast with previous
studies.18,27,28 Conversely, 1 previous study reported a lower
mortality in the EVT-alone group.8 Importantly, the IVT+EVT
group of this study was matched with patients who were
eligible for IVT but were treated with EVT alone at the
physician’s discretion. Because the current standard of care in
The Netherlands is to always give IVT except when con-
traindicated, we could not perform a similar analysis.
The occurrence of sICH and severe extracranial hemorrhage
did not differ between both groups, which is in line with most
previous studies.7,9,16,18 In the HERMES (Highly Effective
Reperfusion evaluated in Multiple Endovascular Stroke Trials)
meta-analysis, the risk of sICH was similar in the IVT+EVT group
and IVT alone group.1 This suggests that the occurrence of sICH
can be mainly attributed to IVT rather than to EVT. Therefore,
our results might be a hallmark of residual (ie, unmeasured)
confounding.
The stratiﬁed analysis revealed that the beneﬁt of IVT before
EVT was not present in patients with pre-existing atrial
ﬁbrillation. While this sensitivity analysis must be interpreted
with caution, it could imply that IVT has a lower treatment effect
in patients with a large vessel occlusion caused by embolism
from the heart than in patients with stroke of other etiology. For
instance, it may be that cardiac thrombi have a different
composition or age than thrombi of noncardiac origin.29 Another
potential explanation could be the risk of sICH. The proportion of
patients who developed a sICH after EVT alone (ie, without prior
IVT) was almost 5% higher in patients without atrial ﬁbrillation
than in patients with atrial ﬁbrillation (7.3% versus 2.8%,
Table 8), which could partly explain the worse outcome of
patientswithout atrialﬁbrillationwho received EVT alone.On the
acOR 1.47 (95%CI: 1.10–1.96) 
Figure 2. Distribution of the modiﬁed Rankin Scale score at 90 days in IVT+EVT group vs EVT-alone
group (%)*. acOR indicates adjusted common odds ratio; EVT, endovascular treatment; IVT, intravenous
thrombolysis; mRS, modiﬁed Rankin Scale. *The mRS 0 to 5 group contains 125 missing cases, whereas
the mRS 6 group is complete. Therefore, this ﬁgure over-represents mortality in both groups.
Table 5. No Recanalization Versus Recanalization Before Start of EVT in Patients With and Without IVT Per Occlusion Location*
IVT+EVT EVT
No Recanalization
Before Start of EVT (n=1015)
Recanalization
Before Start of EVT (n=85)
No Recanalization
Before Start of EVT (n=299)
Recanalization
Before Start of EVT (n=8)
Occlusion location, n (%)*
ICA 66 (94) 4 (5.7) 12 (100) 0 (0)
ICA-T 236 (98) 5 (2.1) 71 (100) 0 (0)
Proximal M1 273 (94) 15 (5.2) 71 (95) 4 (5.3)
Distal M1 310 (89) 39 (11) 111 (100) 0 (0)
M2/M3 125 (85) 22 (15) 34 (92) 3 (8.1)
A1/A2 5 (100) 0 (0) 0 (0) 1 (100)
A1 indicates segment 1 of the anterior cerebral artery; A2, segment 2 of the anterior cerebral artery; EVT, endovascular treatment; ICA, internal carotid artery; ICA-T, terminal internal
carotid artery; IVT, intravenous thrombolysis; M1, segment 1 of middle cerebral artery; M2, segment 2 of middle cerebral artery; M3, segment 3 of middle cerebral artery.
*Missing data on occlusion location: 66. We excluded 12 patients in whom no occlusion was visible on computed tomography angiography after adjudication by the imaging core
laboratory.
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other hand, the difference in response to IVT in patients
with atrial ﬁbrillation could also be the result of residual
confounding.
Finally, it is important to consider the implications of
withholding IVT in patients eligible for both IVT and EVT, in
whom EVT may be delayed or not feasible. This is the case, for
example, when the clot is not accessible because of technical
reasons such as arterial tortuosity and extracranial carotid
stenosis or occlusion.30 In the MR CLEAN trial and Registry,
this occurred in 5% and 6% of all patients, respectively, as
Table 6. Baseline Characteristics After Propensity Score Matching
IVT+EVT (n=305) EVT (n=305) P Value
Age (y), median (IQR) 72 (59–82) 72 (63–80) 0.61
Men, n (%) 165/305 (54) 163/305 (53) 0.87
NIHSS, median (IQR) 16 (11–20) 17 (13–20) 0.13
Systolic BP, mean mm Hg (SD) 149 (25) 149 (26) 0.74
Diastolic BP, mean mm Hg (SD) 82 (16) 82 (17) 0.99
Medical history
Atrial fibrillation, n (%) 102/305 (33) 126/305 (41) 0.045
Diabetes mellitus, n (%) 61/305 (20) 51/305 (17) 0.30
Hypertension, n (%) 157/305 (52) 167/305 (55) 0.42
Ischemic stroke, n (%) 62/305 (20) 74/305 (24) 0.24
Myocardial infarction, n (%) 53/305 (17) 62/305 (20) 0.35
Peripheral artery disease, n (%) 31/305 (10) 35/305 (11) 0.60
Pre-stroke mRS, n (%) 0.06
0 192/305 (63) 161/305 (53)
1 41/305 (13) 54/305 (18)
2 23/305 (7.5) 36/305 (12)
≥3 49/305 (16) 54/305 (18)
Medication
Direct oral anticoagulants, n (%) 10/305 (3.3) 23/305 (7.5) 0.02
Vitamin K antagonists, n (%) 66/305 (22) 107/305 (35) <0.01
Antiplatelets, n (%) 97/305 (32) 98/305 (32) 0.93
Imaging
Occlusion location on CTA, n (%) 0.65
ICA 16/305 (5.3) 12/305 (3.9)
ICA-T 69/305 (23) 77/305 (25)
M1 174/305 (57) 180/305 (59)
M2 41/305 (13) 33/305 (11)
Other* 5/305 (1.6) 3/305 (1.0)
ASPECTS, median (IQR) 8 (7–10) 9 (7–10) 0.66
Collateral score, n (%) 0.82
Grade 0 20/305 (6.6) 24/305 (7.9)
Grade 1 101/305 (33) 94/305 (31)
Grade 2 120/305 (39) 117/305 (38)
Grade 3 64/305 (21) 70/305 (23)
Baseline characteristics of set 1 of 5 imputed data sets are provided. ASPECTS indicates Alberta Stroke Program Early CT Score; BP, blood pressure; CTA, computed tomography
angiography; EVT, endovascular treatment; ICA, internal carotid artery; ICA-T, terminal internal carotid artery; IQR, interquartile range; IVT, intravenous thrombolysis; M1, middle cerebral
artery segment 1; M2, middle cerebral artery segment 2; mRS, modiﬁed Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
*Other: occlusions in segment 1 or 2 of the anterior cerebral artery (A1: n=2; A2: n=2) or no occlusion visible (n=4) on CTA after adjudication by the imaging core laboratory.
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opposed to the other randomized controlled trials that used
more strict selection criteria and that reported percentages
between 2% and 3.6%.20,21,31,32 In such cases, IVT remains
the only available reperfusion therapy.
Table 7. Baseline Characteristics Among Patients Treated With IVT+EVT Versus EVT Alone, Stratiﬁed by Past Medical History of
Atrial Fibrillation
Patients With Atrial Fibrillation Patients Without Atrial Fibrillation
IVT+EVT (n=186) EVT (n=141) P Value IVT+EVT (n=958) EVT (n=179) P Value
Age (y), median (IQR) 77 (68–84) 77 (69–83) 0.75 69 (57–78) 68 (58–76) 0.54
Men, n (%) 87/186 (47) 70/141 (50) 0.61 525/958 (55) 100/179 (56) 0.79
NIHSS, median (IQR)* 16 (12–21) 17 (13–20) 0.36 15 (11–19) 16 (12–20) 0.04
Systolic BP, mean mm Hg (SD)† 148 (130–165) 150 (132–166) 0.54 150 (131–165) 147 (130–165) 0.21
Diastolic BP, mean mm Hg (SD)‡ 84 (70–95) 80 (70–94) 0.70 80 (70–90) 80 (66–92) 0.77
Medical history
Diabetes mellitus, n (%) 34/186 (18) 30/139 (22) 0.46 158/958 (16) 25/178 (14) 0.41
Hypertension, n (%) 114/184 (62) 98/140 (70) 0.13 438/947 (46) 79/177 (45) 0.69
Ischemic stroke, n (%) 36/186 (19) 39/141 (28) 0.08 126/957 (13) 43/178 (24) <0.001
Myocardial infarction, n (%) 27/184 (15) 30/136 (22) 0.09 134/949 (14) 33/176 (19) 0.11
Peripheral artery disease, n (%) 17/181 (9.4) 16/139 (12) 0.54 78/948 (8.2) 20/176 (11) 0.18
Pre-stroke mRS, n (%) 0.27 <0.001
0 111/185 (60) 72/140 (51) 707/938 (75) 91/176 (52)
1 27/185 (15) 23/140 (16) 103/938 (11) 32/176 (18)
2 18/185 (9.7) 12/140 (8.6) 48/938 (5.1) 26/176 (15)
≥3 29/185 (16) 33/140 (24) 80/938 (8.5) 27/176 (15)
Medication
Direct oral anticoagulants, n (%) 7/183 (3.8) 22/138 (16) <0.001 3/944 (0.3) 5/177 (2.8) <0.01
Vitamin K antagonists, n (%) 52/183 (28) 83/141 (59) <0.001 18/952 (1.9) 35/179 (20) <0.001
Antiplatelets, n (%) 60/183 (33) 33/139 (24) 0.08 327/949 (35) 66/177 (37) 0.47
Imaging
Occlusion location on CTA, n (%) 0.02 0.74
ICA 5/175 (2.9) 4/137 (2.9) 65/913 (7.1) 8/165 (4.8)
ICA-T 30/175 (17) 31/137 (23) 208/913 (23) 38/165 (23)
M1 104/175 (59) 91/137 (66) 522/913 (57) 93/165 (56)
M2 35/175 (20) 10/137 (7.3) 106/913 (12) 23/165 (14)
Otherk 1/175 (0.6) 1/137 (0.7) 12/913 (1.3) 3/165 (1.8)
ASPECTS, median (IQR)§ 9 (7–10) 9 (7–10) 0.37 9 (7–10) 9 (7–10) 0.51
Collateral score, n (%) 0.98 0.33
Grade 0 14/168 (8.3) 10/132 (7.6) 56/893 (6.3) 14/167 (8.4)
Grade 1 56/168 (33) 42/132 (32) 304/893 (34) 51/167 (31)
Grade 2 70/168 (42) 58/132 (44) 341/893 (38) 58/167 (35)
Grade 3 28/168 (17) 22/132 (17) 192/893 (22) 44/167 (26)
ASPECTS indicates Alberta Stroke Program Early CT Score; BP, blood pressure; CTA, computed tomography angiography; EVT, endovascular treatment; ICA, internal carotid artery; ICA-T,
terminal internal carotid artery; IVT, intravenous thrombolysis; IQR, interquartile range; M1, middle cerebral artery segment 1; M2, middle cerebral artery segment 2; mRS, modiﬁed Rankin
Scale; NIHSS, National Institutes of Health Stroke Scale.
Missing: *29; †40; ‡45; §64.
kOther: occlusions in segment 1 or 2 of the anterior cerebral artery, segment 3 of the middle cerebral artery, or no occlusion visible on CTA after adjudication by the imaging core laboratory.
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Whether patients with acute ischemic stroke who are
eligible for EVT should still receive intravenous alteplase is
currently heavily debated among stroke physicians and
researchers. In the present study, we explored many aspects
of this debate. In addition to comparing clinical and safety
outcomes in patients with IVT+EVT to those with EVT alone,
we also included a complete assessment of workﬂow and
procedural outcomes. Other strengths of our study include its
comprehensive statistical approach, the large sample size,
adherence to current protocols (eg, not awaiting the effect of
IVT), and central adjudication of neuro-imaging, outcomes,
and complications. Moreover, the data come from a nation-
wide registry and therefore reﬂect routine clinical practice.
Similar to other studies that have tried to examine the added
beneﬁt of IVT before EVT, the main limitation of our study is
the fact that it was nonrandomized. Patients in the EVT-alone
group were selected based on contraindications for IVT. We
also found that patients in the EVT-alone group more often
had a pre-stroke disability, had a higher NIHSS at baseline,
and were more often presented outside the 4.5-hour time
window for IVT (reﬂected in the 16 minutes shorter onset-to-
ﬁrst noncontrast-computed-tomography time in patients with
IVT+EVT). These factors are all associated with a worse
prognosis.33,34 The apparent beneﬁt of prior IVT on functional
outcome remained after adjustment for these factors and
after propensity score matching based on these variables,
yielding comparable point estimates of 1.47 and 1.42,
respectively, but not after stratiﬁcation for atrial ﬁbrillation.
Therefore, we still cannot exclude the possibility of residual
confounding. Secondly, we had no data on whether the full
dose of alteplase was administered in each patient who was
treated with IVT. However, the Dutch stroke guideline does
not advise on halting infusion of alteplase after groin puncture
and/or recanalization. Since this guideline is well adhered to
in The Netherlands, patients most likely received the full dose
of alteplase.35 Thirdly, patients who had a sICH before EVT
and those who recovered before EVT are not represented in
our study, since both types of patients would not have
received EVT and were thus not recorded in the Registry.
Our data show that, in daily clinical practice, administering
IVT before EVT has advantages and disadvantages. Because this
is a nonrandomized study, we cannot ﬁrmly conclude whether
IVT before EVT is beneﬁcial to patients with acute ischemic
stroke caused by an intracranial large vessel occlusion. Patients
treated with both IVT and EVT had a better functional outcome
and lower mortality at 90 days than those with contraindica-
tions for IVT who were treated with EVT alone, also after
adjustment for potential confounders and after propensity
score matching. Notably, in patients with atrial ﬁbrillation, IVT
may not be beneﬁcial before EVT. Our results may indicate
a true added beneﬁt of IVT before EVT in select patient
groups, but the interpretation is hampered by the possibilityTa
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of residual confounding or selection bias, which cannot be
overcome by multivariable regression analysis or propensity
score matching. MR CLEAN-NO IV (ISRCTN10888758), SWIFT-
DIRECT (NCT03192332), DIRECT-SAFE (NCT03494920), and
DIRECT-MT (NCT03469206), the 4 ongoing randomized clinical
trials that directly compare both treatment strategies, will
provide conclusive results on this topic. Meanwhile, IVT should
not be withheld in patients outside these trials who are eligible
for both IVT and EVT.
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